Nuvilex, Inc. Price Valuation Justifies Investors' Confidence in Biotech

NEW YORK, NY--(Marketwired - Apr 25, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is an international biotechnology firm quietly going about its business in Silver Spring, Maryland. The company is currently priced below $0.08/share, and according to a recent valuation report, today's price is highly undervalued given the work being done at Nuvilex.

Goldman Small Cap Research released a valuation of Nuvilex based upon the biotech's work with pancreatic cancer and its future potential in the medical marijuana arena. This valuation gives the company's many shareholders reason to say "I told you so." It is clear investors have a lot of confidence in Nuvilex as the price and accumulation have remained steady while they await the company's upcoming Phase III clinical trial studying its treatment for patients with advanced, inoperable pancreatic cancer.

After several months of research into Nuvilex, Stock House Group, a full service investor relations firm focused on research, market awareness and content development, feels the valuation could be incomplete. Nuvilex's research in the area of diabetes could, in the end, be the company's real bread winner. Goldman clearly made a strong case for Nuvilex's valuation using the company's already accomplished and future research in the areas of cancer and medical marijuana respectively, and while we agree fully with the report, it would be interesting to see a full valuation that includes Nuvilex's future with its diabetes studies, which also uses the company's "Cell-in-a-Box" technology, factored into the equation.

The timing of Nuvilex's research and the astounding results it has demonstrated with its diabetes studies so far, are right in line with the growing necessity for a better treatment for the widespread disease. By 2020, the market for diabetes treatments is projected to reach $65 billion worldwide. According to the International Diabetes Federation, 371 million people around the world have been diagnosed with diabetes and another 187 million remain undiagnosed -- leaving many millions susceptible to the debilitating, and even deadly, complications associated with this disease.

Continue reading the rest of this article at www.stockhousegroup.com/features

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.